Time to tumor regrowth (TTR) of JIMT-1 cells for dosing regimens simulated in the 3DD system
The profile colors are found in Fig. 6B. The TTR was calculated as the horizontal distance between the control arm (black) and treatment profiles, when all growth curves became nearly parallel to one another after cessation of treatment.
| Dosing Regimen | Profile Color | TTR (d) |
|---|---|---|
| Everolimus | ||
| 50 nM for 72 ha | Blue | — |
| Dasatinib | ||
| 50 nM for 72 h | Green | 2.2 |
| DE | ||
| 50 nM for 72 h | Orange | 6.1 |
| Paclitaxel | ||
| 3-h short-term infusion | Pink | 8.6 |
| 50 nM for 72 h | Yellow | 10.9 |
| P(DE) | ||
| Sequential, 120-h interval; 50 nM for 72 h | Orange dashed | 15.4 |
| Sequential, 96-h interval; 50 nM for 72 h | Blue dashed | 15.5 |
| Sequential, 24-h interval; 50 nM for 72 h | Red dashed | 24.3 |
| Sequential, 48-h interval; 50 nM for 72 h | Green dashed | 26.0 |
| Sequential, 72-h interval; 50 nM for 72 h | Yellow dashed | 26.8 |
| Sequential, 24-h interval; 25 nM for 72 h | Gray dashed | 23.1 |
| PDE | ||
| Simultaneous, 50 nM for 72 h | Purple dashed | 24.6 |
| Simultaneous, 25 nM for 72 h | Black dashed | 22.9 |
DE, dasatinib + everolimus simultaneous treatment; PDE, paclitaxel + dasatinib + everolimus treatment; P(DE), paclitaxel followed by dasatinib + everolimus sequential treatment.
↵a The TTR for everolimus was not calculated due to lack of a significant cytostatic/cytotoxic effect. Its profile nearly overlapped with the control profile.